Physician profile
Sara Downs
NPI 1548384480
$7,188.86
in general payments reported to CMS, 2019-2025
36 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $1,626 · 2021: $1,294 · 2022: $773 · 2023: $1,066 · 2024: $894 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,562.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,920.71 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $890.93 | 2019-2024 | Jardiance |
| Abbvie INC. | $761.00 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $584.09 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $416.92 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $386.44 | 2020-2023 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $384.96 | 2020-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $195.13 | 2019-2021 | |
| Amarin Pharma, INC. | $164.83 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $164.03 | 2024-2025 | Voquezna |
| Abbott Laboratories | $153.76 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $112.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.48 | 2021-2023 | |
| Amgen INC. | $101.10 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.09 | 2020-2024 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $90.31 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $85.36 | 2019-2021 | |
| Astellas Pharma US INC | $64.65 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $62.66 | 2019-2021 | |
| Insulet Corporation | $58.33 | 2020-2024 | Omnipod |
| Pfizer INC. | $56.44 | 2019-2021 | |
| Allergan, INC. | $49.90 | 2019-2020 | |
| Esperion Therapeutics, INC. | $36.99 | 2021 | |
| Axsome Therapeutics, INC. | $31.05 | 2023 | Sunosi |
| Jazz Pharmaceuticals INC. | $22.44 | 2021 | |
| Dexcom, INC. | $22.33 | 2020 | |
| Hologic Sales and Service, LLC | $21.78 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $19.76 | 2020 | |
| Companion Medical, INC. | $17.77 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.91 | 2023 | Quviviq |
| Medline Industries Lp | $15.75 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.19 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.88 | 2022 | |
| Corcept Therapeutics | $14.38 | 2019 | |
| Shire North American Group INC | $13.36 | 2019 | |
| Sanofi Pasteur INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.